Please type a plus sign (+) inside this box → [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

OIPE JUL 3 0 2002 PATENT & TRADEMARK OFFICE

Substitute for form 1449APTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

RECEIVED
AUG 0 5 2002
TECH CENTER 1600/2900

Complete if Known	
Application Number	10/091,759
Filing Date	March 5, 2002
First Named Inventor	Adnan M.M. Mjalli
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	41305-271123 (20[illegible]
Express Mail Certificate	EV 032 196 842 US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.¹	U.S. Patent Document Number	Kind Code² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
MD	1	4,166,452		Generales, Jr.	09-04-79	
	2	4,265,874		Bonsen, et al.	05-05-81	
	3	4,356,108		Schwab, et al.	10-26-82	
	4	4,873,313		Crawford, et al.	10-10-89	
	5	5,202,424		Vlassara, et al.	04-13-93	
	6	5,585,344		Vlassara, et al.	12-17-96	
	7	5,688,653		Ulrich, et al.	11-18-97	
	8	5,864,018		Morser, et al.	01-26-99	
	9	5,939,526		Gaugler, et al.	08-17-99	
MD	10	6,100,098		Newkirk	08-08-00	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.¹	Office³	Number⁴	Kind Code² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁶
MD	11	WO	00/20458		The Trustees of Columbia University in NYC	04-13-00		✓
	12	WO	00/20621		The Trustees of Columbia University in NYC	04-13-00		✓
	13	WO	97/26913		The Trustees of Columbia University in NYC	07-31-97		✓
	14	WO	97/39121		Schering Aktiengesellschaft	10-23-97		✓
	15	WO	9739125		Schering Aktiengesellschaft	10-23-97		✓
	16	WO	98/22138		The Trustees of Columbia University in NYC	05-28-98		✓
	17	WO	99/07402		The Trustees of Columbia University in NYC	02-18-99		✓
	18	WO	99/18987		The Trustees of Columbia University in NYC	04-22-99		✓
	19	WO	99/54485		The Trustees of Columbia University in NYC	10-28-99		✓
	20	WO	95/09838		Merrell Dow Pharmaceuticals Inc.	04-13-95		✓
	21	WO	95/35279		Merrell Pharmaceuticals Inc.	12-28-95		✓
	22	WO	97/22618		Vertex Pharmaceuticals Incorporated	06-26-97		✓
	23	WO	96/32385		Hoechst Marion Roussel Inc.	10-17-96		✓
MD	24	WO	99/50230		Vertex Pharmaceuticals Incorporated	10-07-99		✓

March 2004

Please type a plus sign (+) inside this box → [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Complete if Known	
Application Number	10/091,759
Filing Date	March 5, 2002
First Named Inventor	Adnan M.M. Mjalli
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	41305-271123 (200[illegible])
Express Mail Certificate	EV 032 196 842 US

	25	GB	2 005 674			Carlo Erba S.p.A.		04-25-79		✓
	26	WO	98/33492			Fox Chase Cancer Center		08-06-98		✓
	27	WO	99/25690			University of Kansas Medical Center		05-27-99		✓
	28	WO	01/12598			The Trustees of Columbia University in New York City, NY		02-22-01		✓

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	29	Albercio, F. & Carpino, L.A., "Coupling Reagents and Activation" *Methods in Enzymology* 289:104-126, Academic Press, San Diego (1997)	✓
	30	Barton, J.W., " In Protection of N-H Bonds and NR_3" *Protective Groups in Organic Chemistry*, J.F.W. McOmie, ED., Plenum Press, New York, NY (1973)	✓
	31	Berge, S.M., et al., "Pharmaceutical Salts" *Journal of Pharmaceutical Sciences* 66:1-19 (1977)	✓
	32	Chitaley, K., et al., "Antagonism of Rho-Kinase Stimulates Rate Penile Erection via a Nitric Oxide-Independent Pathway" *Nature Medicine* 7:119-122 (2002)	✓
	33	Degenhardt, T.P., et al., "Chemical Modification of Proteins by Methylglyoxal" *Cell Mol. Biol.*, 44:1139-1145 (1998)	✓
	34	Dyer, D.G., et al., "Accumulation of Maillard Reaction Products in Skin Collagen in Diabetes and Aging" *J. Clin. Invest.*, 91:2463-2469 (1993)	✓
	35	Dyer, D.G., et al., "Formation of Pentosidine during Nonenzymatic Browning of Proteins by Glucose" *J. Biol. Chem.*, 266:11654-11660 (1991)	✓
	36	Greene, T.W.," Protection for the Amino Group" *Protective Groups in Organic Synthesis*, John Wiley and Sons, New York, NY, Chapter 7 (1981)	✓
	37	Hammes, H.P., et al., "Diabetic Retinopathy Risk Correlates with Intracellular Concentrations of the Glycoxidation Product N^{ε}-(Carboxymethyl) Lysine Independently of Glycohaemoglobin Concentrations" Diabetologia, 42:603-607 (1999)	✓
	38	Hoffman, M.A., et al., "RAGE Mediates a Novel Proinflammatory Axis: A Central Cell Surface Receptor for S100/Calgranulin Polypeptides" *Cell*, 97:889-901 (1999)	✓
	39	Hori, O., et al., "The Receptor for Advanced Glycation End Products (RAGE) is a Cellular Binding site for Amphoterin" *J. Biol. Chem.*, 270:25752-761 (1995)	✓
	40	Huttunen, H.J., et al., "Receptor for Advanced Glycation End Products (RAGE)-Mediated Neurite Outgrowth and Activation of NF-Kappa B Require the Cytoplasmic Domain of the Receptor But Different Downstream Signaling Pathways" *J. Biol. Chem.* 274(28):19919-24 (1999)	✓

March 2004

Please type a plus sign (+) inside this box → ☐+

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

+

Substitute for form 1449APTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	10/091,759
Filing Date	March 5, 2002
First Named Inventor	Adnan M.M. Mjalli
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	41305-271123 (2001-
Express Mail Certificate	EV 032 196 842 US

Sheet 3 of 4

	41	Kumar, S.R., et al., "RAGE at the Blood-Brain Barrier Mediates Neurovascular Dysfunction Caused by Amyloidβ_{1-40} Peptide" *Neurosci. Program*, 141-#255.19 **(2000)**	✓
	42	Leder, A. et al., "v-HA-*ras* Transgene Abrogates the Initiation Step in Mouse Skin Tumorigenesis: Effects of Phorbol Esters and Retinoic Acid" *Proc. Natl. Acad. Sci., USA*, 87:9178-9182 **(1990)**	✓
	43	Li, J. et al., "Sp1-Binding elements in the Promoter of RAG Are Essential for Amphoterin-Mediated Gene Expression in Cultured Neuroblastoma Cells." *J. Biol. Chem.*, 273:30870-30878 **(1998)**	✓
	44	Li, J. et al., "Characterization and Functional Analysis of the Promoter of RAGE, the Receptor for Advanced Glycation End Products," *J. Biol. Chem.*, 272:16498-16506 **(1997)**	✓
	45	Lugering, N. et al., "The Myeloic Related Protein MRP8/14 (27E10 Antigen)—Usefulness as a Potential Marker for Disease Activity in Ulcerative Colitis and Putative Biological Function" Eur. J. Clin. Invest., 25:659-664 **(1995)**	✓
	46	Miyata, T. et al., "β_2-Microglobulin Modified with Advanced Glycation End Products Is a Major Component of Hemodialysis-Associated Amyloidosis" *J. Clin. Invest.*, 92:1243-1252 **(1993)**	✓
	47	Miyata, T. et al., "The Receptor for Advanced Glycation End Products (RAGE) Is a Central Mediator of the Interaction of AGE-β_2Microglobulin with Human Mononuclear Phagocytes Via an Oxidant-Sensitive Pathway" *J. Clin. Invest.*, 98:1088-1094 **(1996)**	✓
	48	Neeper, M., et al., "Cloning and Expression of a Cell Surface Receptor for Advanced Glycosylation End Products of Proteins" *J. Biol. Chem.*, 267:14998-15004 **(1992)**	✓
	49	Parkkinen, J. et al., "Amphoterin, the 30-kDa Protein in a Family of HMG1-Type Polypeptides" *J. Biol Chem.*, 268:19726-19738 **(1993)**	✓
	50	Rammes, A. et al., "Myeloid-Related Protein (MRP) 8 and MRP 14, Calcium-Binding Proteins of the S100 Family, Are Secreted by Activated Monocytes via a Novel, Tubulin-Dependent Pathway *J. Biol. Chem.*, 272:9496-9502 **(1997)**	✓
	51	Rauvala, H. et al., "Isolation and Some Characteristics of an Adhesive Factor of Brain That Enhances Neurite Outgrowth in Central Neurons" *J. Biol. Chem.*, 262:16625-16635 **(1987)**	✓
	52	Reddy, S. et al., "N$^\epsilon$-(Carboxymethyl) Lysine Is a Dominant Advanced Glycation End Product (AGE) Antigen in Tissue Proteins" *Biochem.*, 34:10872-10878 **(1995)**	✓
	53	Schafer, B.W., et al., "The S100 Family of EF-Hand Calcium-Binding Proteins: Functions and Pathology" *TIBS*, 21:134-140 **(1996)**	✓
	54	Schleicher, E.D., et al., "Increased Accumulation of the Glycoxidation Product N$^\epsilon$-(Carboxymethyl) Lysine in Human Tissues in Diabetes and Aging" *J. Clin. Invest.*, 99(3):457-468 **(1997)**	✓
	55	Schmidt, A.M. et al., "The Dark Side of Glucose" *Nature Med.*, 1:1002-1004 **(1995)**	✓

March 2004

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 4

Complete if Known	
Application Number	10/091,759
Filing Date	March 5, 2002
First Named Inventor	Adnan M.M. Mjalli
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	41305-271123 (2001-21)
Express Mail Certificate	EV 032 196 842 US

	56	Schmidt, A.M., et al., "The V-Domain of Receptor for Advanced Glycation Endproducts (RAGE) Mediates Binding of AGEs: A Novel Target for Therapy of Diabetic Complications:" *Supplement to Circulation* Vol. 96, #194 (1997)	✓
	57	Taguchi, A. et al., "Blockade of RAGE—Amphoterin Signalling Suppresses Tumour Growth and Metastases" *Nature*, 405:354-360 (2000)	✓
	58	Tanaka, N., et al., "The Receptor for Advanced Glycation End Products Is Induced by the Glycation Products Themselves and Tumor Necrosis Factor-α through Nuclear Factor-κB, and by 17β-Estradoil through Sp-1 in Human Vascular Endothelial Cells"*J. Biol. Chem.*, 275:25781-25790 (2000)	✓
	59	Teillet et al., "Food Restriction Prevents Advanced Glycation End Product Accumulation and Retards Kidney Aging in Lean Rats" *J. Am. Soc. Nephrol.*, 11:1488-1497 (2000)	✓
	60	Vlassara, H., "Advanced Glycation End-Products and Atherosclerosis" *The Finnish Medical Society DUODECIM, Ann. Med.*, 28:419-426 (1996)	✓
	61	Wautier et al., "Receptor-Mediated Endothelial Cell Dysfunction in Diabetic Vasculopathy: Soluble Receptor for Advanced Glycation End Products Blocks Hyperpermeability in Diabetic Rats" *J. Clin. Invest.*, 97:238-243 (1996)	✓
	62	Yan, S.-D., et al., "RAGE and Amyloid-β Peptide Neurotoxicity in Alzheimer's Disease" *Nature* 382:685-691 (1996)	✓
	63	Yan, S.-D., et al., "An Intracellular Protein That Binds Amyloid-β Peptide and Mediates Neurotoxicity in Alzheimer's Disease" *Nature*, 389:689-695, (1997)	✓
	64	Yan, S.-D. et al., "Amyloid-β Peptide—Receptor for Advanced Glycation Endproduct Interaction Elicits Neuronal Expression of Macrophage-Colony Stimulating Factor: A Proinflammatory Pathway in Alzheimer Disease" *Proc. Natl. Acad. Sci., USA*, 94:5296-5301 (1997)	✓
	65	Yan, S.-D. et al., "Receptor-Dependent Cell Stress and Amyloid Accumulation in Systemic Amyloidosis" *Nat. Med.* 6:643-651 (2000)	✓
	66	Yan, S.-D. et al., "Enhanced Cellular Oxidant Stress by the Interaction of Advanced Glycation Endproducts With Their Receptors Binding Proteins" J. Biol. Chem. 269:9889-9897 (1994)	✓
	67	Zimmer, D. et al., The S100 Protein Family: History, Function, and Expression" *Brain Res. Bull*, 37:417-429 (1995)	✓
	68	International Search Report for PCT/US 01/17251 dated 8/14/01	✓

Examiner Signature		Date Considered	March 2004

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.